Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transduction of leptin growth signals in placental cells is independent of JAK-STAT activation.

Placenta·2003
Same author

Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function.

The Journal of clinical endocrinology and metabolism·2002
Same author

[Antidiabetic effect of thiazolidinediones].

Journees annuelles de diabetologie de l'Hotel-Dieu·2001
Same author

Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights.

Diabetes & metabolism·2001
Same author

Dissociation between insulin-mediated signaling pathways and biological effects in placental cells: role of protein kinase B and MAPK phosphorylation.

Endocrinology·2001
Same author

[Mechanisms of action of thiazolidinediones].

Diabetes & metabolism·2001

Related Experiment Video

Updated: Jun 30, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

[PPARgamma and insulin resistance].

J Girard1

  • 1Endocrinologie et Métabolisme, Faculté de Médecine Cochin, F - 75014 Paris, France.

Annales D'Endocrinologie
|May 31, 2002
PubMed
Summary

Thiazolidinediones (TZD) improve insulin sensitivity and glucose metabolism. This study investigates the paradox of how TZDs, acting mainly in adipose tissue, enhance glucose uptake in skeletal muscle, which has limited PPARgamma.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Thiazolidinediones (TZD) are oral antidiabetic agents that enhance insulin sensitivity.
  • TZDs have demonstrated efficacy in correcting hyperglycemia and hyperinsulinism in NIDDM models and human studies.
  • Clinical evidence shows TZDs reduce postprandial and postabsorptive glycemia and insulinemia.

Purpose of the Study:

  • To investigate the mechanism by which TZDs improve glucose metabolism in skeletal muscle.
  • To address the paradox of TZD action, given their primary site of action in adipose tissue and the limited PPARgamma in skeletal muscle.

Main Methods:

  • Review of existing clinical and animal studies on TZD action.
  • Analysis of the role of PPARgamma and its isoforms in insulin sensitivity.
  • Exploration of molecular pathways linking adipose tissue and skeletal muscle metabolism.

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Related Experiment Videos

Last Updated: Jun 30, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Main Results:

  • Glucose clamp studies indicate a 30% improvement in insulin-induced glucose utilization in skeletal muscle with TZD treatment.
  • TZDs bind to Peroxisome Proliferator-Activated Receptor gamma (PPARgamma), a nuclear receptor influencing gene transcription.
  • PPARgamma activation leads to downstream effects impacting glucose metabolism.

Conclusions:

  • TZDs enhance skeletal muscle glucose uptake despite limited PPARgamma expression in this tissue.
  • The study aims to elucidate the signaling pathways responsible for this TZD-mediated improvement in glucose metabolism.
  • Understanding this mechanism could lead to more targeted therapies for NIDDM.